Interstitial Lung Abnormalities and Lung Cancer Risk in the National Lung Screening Trial.

CONCLUSIONS: Asymptomatic interstitial lung abnormalities are an independent risk factor for lung cancer which can be incorporated into risk score models. PMID: 31404527 [PubMed - as supplied by publisher]
Source: Chest - Category: Respiratory Medicine Authors: Tags: Chest Source Type: research

Related Links:

The safety of treatment with immune ‐checkpoint inhibitors prior to thoracic surgery in patients with non‐small cell lung cancer (NSCLC) remains unclear. Here, we describe the case of a 62‐year‐old woman with NSCLC with programmed death ligand 1 expression on 85% of tumor cells. The patient was initially considered to have unr esectable stage IIIB disease and received pembrolizumab monotherapy. After 12 cycles of pembrolizumab, the primary tumor was reduced, but a small lung nodule in another lobe was unchanged. Based on the course of image findings, the nodule was considered to be an old inflammatory change...
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: CASE REPORT Source Type: research
ConclusionCIP is a serious complication with a poor prognosis associated with high mortality. The efficacy of ICI is significantly worse in patients with severe grade CIP than in those without severe grade CIP. Whether ICIs should be administered to patients with CIP risk factors, such as an ECOG PS score of ≥2 or pre‐existing ILD, should be carefully assessed.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Conditions:   Interstitial Lung Disease;   Lung Cancer Intervention:   Sponsor:   Portsmouth Hospitals NHS Trust Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusion.This S‐1 and PTX cotherapy dose and schedule showed satisfactory efficacy, with mild toxicities, in patients with previously treated advanced NSCLC.
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Lung Cancer, Chinese Edition, Clinical Trial Results Source Type: research
Publication date: 15 September 2019Source: Life Sciences, Volume 233Author(s): Shweta Arora, Shaniya Ahmad, Rasha Irshad, Yamini Goyal, Sahar Rafat, Neha Siddiqui, Kapil Dev, Mohammad Husain, Shakir Ali, Anant Mohan, Mansoor Ali SyedAbstractToll-like receptors (TLRs) comprise a clan of proteins involved in identification and triggering a suitable response against pathogenic attacks. As lung is steadily exposed to multiple infectious agents, antigens and host-derived danger signals, the inhabiting stromal and myeloid cells of the lung express an aggregate of TLRs which perceive the endogenously derived damage-associated mol...
Source: Life Sciences - Category: Biology Source Type: research
Rationale: Pembrolizumab, an immune-checkpoint inhibitor (ICI), has been shown to be effective for treatment-naive patients with non–small cell lung cancer (NSCLC) and high expression of programmed death-ligand 1 (PD-L1). Therefore, treatment regimens containing pembrolizumab have become a standard therapy for these patients. However, the use of pembrolizumab is limited owing to the side effects of ICIs. Patient concerns and diagnoses: The patient was a 65-year-old man with a left lung mass surrounded by interstitial shadow. The tumor was diagnosed as adenocarcinoma, cT4N3M0, stage IIIC, and the tumor cells show...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
President Donald Trump on Monday signed legislation that will extend the September 11th Victim Compensation Fund until 2092. During the signing ceremony at the White House, Trump was surrounding by first responders, survivors and family members of several who died in the 2001 terrorist attack on the United States. The U.S. House of Representatives and the U.S Senate voted overwhelmingly last week to approve the legislation that will provide a lifetime of assistance for victims and their families. The extension will allow the fund, first established in 2001, to pay for past and future medical claims of those effected by the...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
The U.S. Senate followed the House of Representatives on Tuesday and passed legislation that will extend the September 11 Victim Compensation Fund until 2092. The legislation will fund all current and future medical claims of those effected by the 9/11 terrorist attacks on the World Trade Center in New York City, the Pentagon in Washington, and United Flight 93, which crashed in Shanksville, Pennsylvania. The extension of funding will benefit victims who may develop mesothelioma linked to the more than 400 tons of asbestos that covered the 16-acre disaster zone after the twin towers fell. According to World Trade Center R...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Rationale: IgG4-related disease is a rare and novel disease entity that tends to involve multiple organs. The pulmonary manifestation of this disease is highly variable and may mimic lung cancer, pneumonia, interstitial lung disease (ILD), sarcoidosis, and so forth. Small airway disease is rarely reported in IgG4-related lung disease (IgG4-RLD). In the current study, we describe a rare case of IgG4-RLD with patterns of ILD and bronchiolitis. Patient concern: A 43-year-old man had chronic cough and dyspnea on exertion for 4 years. Initial chest radiography showed diffuse interstitial infiltration. Follow-up chest compu...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
Conclusion Interstitial lung disease occurred in 3.3% of the patients in our study; this appeared to be less frequent than the rates in previous reports. Preexisting pulmonary fibrosis may be a risk factor for interstitial lung disease; however, no fatal cases were found among the patients with asymptomatic pulmonary fibrosis without honeycomb lung. It is thus considered to be necessary to carefully assess the possibility of preexisting pulmonary fibrosis and clarify the presence or absence of honeycomb lung before starting amrubicin chemotherapy.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Tags: Original article Source Type: research
More News: Cancer | Cancer & Oncology | CT Scan | Interstitial Lung Disease | Lung Cancer | Radiography | Respiratory Medicine | Science